#ASCO25

🔥 MATTERNHORN: adding #Durvalumab to FLOT GEJ/GC ADK resectable

🗣️ Dr. Janjigian

✅ DFS 67 vs 57% at 24m HR 0.71
✅ mOS 76 vs 70% at 24m
✅ pCR 19 vs 7%
90% PD-L1+

#OncoNexion25
@oncoalert.bsky.social
@ascocancer.bsky.social @vhio.bsky.social
@myesmo.bsky.social

#ASCO25

Drug development track 🔥

IZA-BREN/BL-B01D1

💉 EGFR-HER3 bispecific ADC (TOP I) #NSCLC
☣️ Hematological
☣️ 1 ILD G2, no deaths

✅ORR 45.6%
✅ Exon 20ins: 85%, HERm: 61.5%
✅ SCLC ORR 75%!

#OncoNexion25 @oncoalert.bsky.social
@myesmo.bsky.social @ascocancer.bsky.social
@vhio.bsky.social